Basic HTML Version
VOLUME 9 NUMBER 1 • MARCH 2012
21
SA JOURNAL OF DIABETES & VASCULAR DISEASE
RESEARCH ARTICLE
Leslie E, Geoffrey J, James M. Statistical analysis. In:
22.
Interpretation and
Uses of Medical Statistics.
4th edn. Oxford: Scientific Publications, 1991: 411–
416.
Braunwald E. Shattuck lecture – cardiovascular medicine at the turn of the
23.
millennium: triumphs, concerns, and opportunities.
N Engl J Med
1997;
337
:
1360–1369.
Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease:
24.
origin and development of ideas. In:
The kidney and Hypertension in Diabetes
Mellitus.
5th edn. Boston: Mosby, 2000: 655–706.
Forbes J
25.
M, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER,
et
al.
Modulation of soluble receptor for advanced glycation end products by
angiotensin-converting enzyme-1 inhibition in diabetic nephropathy
. J Am Soc
Nephrol
2005;
16
: 2363–2372.
Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased
26.
serum concentrations of soluble receptor for advanced glycation endproducts in
patients with type 1 diabetes.
Clin Chem
2005;
51
: 1749–1750.
Brownlee M, Cerami A, Vlassara H. AGEs in tissue and the biochemical basis of
27.
diabetic complications.
N Engl J Med
1988;
318
: 1315–1321.
Abdella N, Al Awadi F, Salman A, Armstrong D. Thiobarbituric acid test as a
28.
measure of lipid peroxidation in Arab patients with NIDDM.
Diabetes Res
1990;
15
: 173–177.
Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of
29.
oxidative stress in the onset and progression of diabetes and its complications:
a summary of a Congress Series sponsored by UNESCO-MCBN, the American
Diabetes Association, and the German Diabetes Society.
Diabetes Metab Res Rev
2001;
17
: 189–212.
Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of
30.
developing type 2 diabetes in women
. Diabetes
2004;
53
: 693–700.
Navarro JF, Mora C. Role of inflammation in diabetic complications.
31.
Nephrol Dial
Transplant
2005;
20
: 2601–2604.
Grossin
32.
N, Wautier MP, Meas T, Guillausseau PJ, Massin P, Wautier JL. Severity of
diabetic microvascular complications is associated with low soluble RAGE level.
Diabetes Metab
2008;
34
: 392–395.
Navarro JF, Mora C, Maca M, Garca J. Inflammatory parameters are independently
33.
associated with urinary albumin excretion in type 2 diabetes mellitus.
Am J Kidney
Dis
2003;
42
: 53–61.
MaCarthy E, Sharma R, Sharma M. TNF-
34.
α
increases albumin permeability of
isolated rat glomeruli through the generation of superoxide.
J Am Soc Nephrol
1998;
9
: 433–438.
Dave GS, Kalia K. Hyperglycemia induced oxidative stress in type-1 and type-2
35.
diabetic patients with and without nephropathy.
Cell Mol Biol
2007;
53
: 68–78.
Polak
36.
M, Zagorski Z. Lipid peroxidation in diabetic retinopathy.
Ann Univ Mariae
Curie Skladowska Med
2004;
59
: 434–437.
Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H. Roles of the
37.
receptor for advanced glycation end products in diabetes-induced vascular injury.
J Pharmacol Sci
2005;
97
: 305–311.
Haslbeck KM, Neundorfer B, Schlotzer-Schrehardtt U, Bierhaus A, Schleicher
38.
E, Pauli E,
et al.
Activation of the RAGE pathway: a general mechanism in the
pathogenesis of polyneuropathies?
Neurol Res
2007;
29
: 103–110.
Carrington AL, Litchfield JE. The aldose reductase pathway and nonenzymatic
39.
glycation in the pathogenesis of diabetic neuropathy: A critical review for the end
of the 20th century.
Diabetes Rev
1999;
7
: 275–299.
Gallou
40.
G, Ruelland A, Campion L, Maugendre D, Le Moullec N, Legras B,
et al
.
Increase in TBARS and vascular complications in type 2 diabetes mellitus.
Diabetes
Metab
1994;
20
: 258–264.
Turk H
41.
M, Sevinc A, Camci C, Cigli A, Buyukberber S, Savli H,
et al
. Plasma lipid
peroxidation products and antioxidant enzyme activities in patients with type 2
diabetes mellitus.
Acta Diabetol
2002;
39
: 117–122.
Nakamura
42.
K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T,
et al
. Elevation of soluble form of receptor for advanced glycation end products
(sRAGE) in diabetic subjects with coronary artery disease.
Diabetes Metab Res Rev
2007;
23
: 368–371.
Tuttl
43.
eHA, Davis-GormanG, Goldman S, Copeland JG,McDonagh PF. Proinflammatory
cytokines are increased in type 2 diabetic women with cardiovascular disease
. J
Diabetes Complicat
2004;
18
: 343–351.
Kesavulu M
44.
M, Rao BK, Giri R, Vijaya J, Subramanyam G, Apparao C. Lipid
peroxidation and antioxidant enzyme status in Type 2 diabetics with coronary
heart disease.
Diabetes Res Clin Pract
2001;
53
: 33–39.
Lapolla
45.
A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R,
et al
. Advanced
glycation end products and antioxidant status in type 2 diabetic patients with and
without peripheral artery disease.
Diabetes Care
2007;
30
: 670–676.
Diary for 2012 cardiovascular congresses
DATE
PLACE
CONFERENCE
18–21 April
Dubai, United Arab Emirates
World Congress of Cardiology
www.world-heart-federation.org
17–20 May
Berlin, Germany
Congress on Cardiac Problems in Pregnancy (CPP 2012)
www.cppcongress.com
18-20 May
Cape Town International
Convention Centre
First annual congress of the Faculty of Consulting Physicians of South Africa
www.physician.co.za
27 June
Frankfurt, Germany
iCi 2012 – Imaging in Cardiovascular Interventions
www.ici-congress.org
28 June
Frankfurt, Germany
CSI 2012 – Catheter Interventions in Congenital and Structural Heart Disease
19–22 July
Sun City, South Africa
13th Annual SA Heart Congress
www.saheart.org
25–29 August
Munich, Germany
2012 ESC, European Society of Cardiology Congress
www.escardio.org